Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of PeptiDream Inc.. A complete text table follows the diagram.
Drug-discovery revenue fell 97.3% and swung to a JPY3.017B loss after a large prior-year collaboration cycle, while radiopharma profit improved to JPY436M.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Radiopharmaceuticals business | 1 | 7.8B | 91.1% of reported total |
| Drug discovery and development business | 1 | 761M | 8.9% of reported total |
| External customer revenue | 2 | 8.5B | Reported six-month revenue across the two disclosed strategic segments |
| Operating loss | 2 | 2.6B | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 11.2B | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| Radiopharmaceuticals business | External customer revenue | 7.8B |
| Drug discovery and development business | External customer revenue | 761M |
| External customer revenue | Operating costs & expenses | 8.5B |
| Operating loss | Operating costs & expenses | 2.6B |